Previous close | 0.1000 |
Open | 0.0500 |
Bid | 0.0000 |
Ask | 0.1000 |
Strike | 190.00 |
Expiry date | 2024-05-17 |
Day's range | 0.0500 - 0.0500 |
Contract range | N/A |
Volume | |
Open interest | 224 |
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of its first trimester preeclampsia screening test to be performed between 11 and 14 weeks gestation to determine the risk of developing preeclampsia before 34 weeks of pregnancy. It is the only test of its kind available in the United States and is relevant for all pregnant individuals, including those with a low- to average-risk for preeclampsia or first-time pregnancies.
Investors are optimistic about Labcorp (LH), led by strategic acquisitions and strong expansion in the Biopharma Laboratory.
Key Insights Laboratory Corporation of America Holdings will host its Annual General Meeting on 14th of May Total pay...